

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ABL301
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ABL301 is a Antibody drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 07, 2023
Lead Product(s) : ABL301
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ABL301
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Sanofi
Deal Size : $1,060.0 million
Deal Type : Collaboration
Details : ABL and SANOFI to collaborate on the development of ABL301, a potential first-in-class bispecific antibody targeting alpha-synuclein and containing a proprietary brain shuttle, for alpha-synucleinopathies, including Parkinson's disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : $75.0 million
January 11, 2022
Lead Product(s) : ABL301
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Sanofi
Deal Size : $1,060.0 million
Deal Type : Collaboration
